Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2026)

Contineum Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 11.33% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $8.5 million (down 10.7% YoY), while the FY2025 annual figure was $8.2 million, down 7.4% from the prior year.
• Interest & Investment Income was $2.5 million for Q1 2026 at Contineum Therapeutics, up from $2.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.7 million in Q3 2024 to a low of $401000.0 in Q1 2023.
• Historically, Interest & Investment Income has averaged $1.9 million across 4 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Interest & Investment Income surged 307.98% in 2024, then retreated 28.6% in 2025.
• A 4-year view of Interest & Investment Income shows it stood at $1.8 million in 2023, then surged by 41.23% to $2.5 million in 2024, then slipped by 20.49% to $2.0 million in 2025, then gained by 24.63% to $2.5 million in 2026.
• The last three Interest & Investment Income figures came in at $2.5 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.